Skip to content

Iron Fortified Food to Improve Japanese Encephalitis and Typhoid Fever Vaccine Immunogenicity

Iron Fortified Food to Improve Japanese Encephalitis and Typhoid Fever Vaccine Immunogenicity: a Randomized Controlled Trial in Iron Deficient Thai Women

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06027801
Enrollment
150
Registered
2023-09-07
Start date
2023-09-06
Completion date
2024-12-30
Last updated
2023-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Iron Deficiency Anemia

Brief summary

Iron deficiency (ID) anaemia (IDA) is a global public health problem, with the highest prevalence in Africa and in South-East Asia. While immunization programs have achieved high global coverage, vaccines often underperform in low- and middle-income countries (LMIC). The cause remains uncertain, but undernutrition, including ID, likely plays a role. Our recent in vitro and in vivo studies have shown the importance of iron status in adaptive immunity and vaccine response. Hypoferremia blunted T cell, B cell, and neutralizing antibody responses to influenza virus infection in mice, allowing the virus to persist. Iron deficient anaemic Kenyan women receiving intravenous iron at time of vaccination had a better immune response to the first dose of the ChAdOx Coronavirus 19 (COVID-19) vaccine and yellow fever vaccine. Japanese encephalitis and typhoid fever are endemic in Thailand. Vaccines are available but show variable efficacy. Whether ID impairs adult vaccine response to the live attenuated Japanese encephalitis (JE) and the Typhoid Vi polysaccharide (Vi-PS) vaccine and whether iron repletion via iron fortification improves vaccine response is uncertain. The objective of this study is to assess whether IDA in Thai women impairs immune response to the JE and the Typhoid Vi-PS vaccine and whether fortification iron improves their response. In this double-blind randomized controlled trial, IDA women will be assigned to two study groups: group 1 (fortification group) will receive iron-fortified biscuits (15mg iron as ferrous fumarate) for 56 days; group 2 (control group) will receive non-fortified biscuits for 56 days. All women will receive live attenuated JE and Typhoid Vi-PS vaccine on study day 28. Vaccine response will be measured 28 days after vaccination (on day 56) in both groups.

Interventions

OTHERIron-fortified cookies

Study cookies fortified with ferrous fumarate, providing 15 mg of elemental iron in each portion.

BIOLOGICALJapanese encephalitis (JE) vaccine

All participants will be administered the live attenuated JE vaccine

BIOLOGICALTyphoid Vi polysaccharide (Vi-PS) vaccine

All participants will be administered the typhoid Vi-PS vaccine

OTHERnon-fortified cookies

Study cookies containing no iron

Sponsors

Mahidol University
CollaboratorOTHER
Ministry of Health, Thailand
CollaboratorOTHER_GOV
University of Oxford
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 49 Years
Healthy volunteers
Yes

Inclusion criteria

* Participant is willing and able to give informed consent for participation in the trial. * Female aged 18-49 years. * Diagnosed with anaemia (i.e. hemoglobin (Hb) concentration \<12 g/dl), but no severe anaemia (Hb \<8 g/dl), and iron deficiency (ZnPP \>40 µmol/mol) * Anticipated residence in the area for the study duration

Exclusion criteria

* Pregnant (confirmed by rapid test during screening and at time of vaccination), lactating or planning pregnancy during the trial. * Blood transfusion or intravenous iron treatment within 4 months of study start * Major chronic infectious disease (e.g., tuberculosis, HIV+, hepatitis) * Major chronic non-infectious disease (e.g., Type 1 or 2 diabetes, cancer) * Treatment with supplemental iron two weeks prior to enrolment * JE or typhoid vaccine within the past two years

Design outcomes

Primary

MeasureTime frame
Immunoglobulin G (IgG) concentrations against Salmonella Typhiday 28 (time of vaccination)
Immunoglobulin A (IgA) concentrations against Salmonella Typhiday 28 (time of vaccination)
Neutralizing antibodies against Japanese encephalitisday 28 (time of vaccination)

Secondary

MeasureTime frame
retinol-binding protein concentration (µmol/L)day 0
Hemoglobin concentration (g/dL)day 0
zinc protoporphyrin (ZnPP) concentration (µmol/mol heme)day 0
serum iron (SFe) concentration (ng/µl)day 0
total iron binding capacity (µg/dL)day 0
transferrin saturation (TSAT) (%)day 0
soluble transferrin receptor (sTfR) concentration (mg/L)day 56
plasma ferritin (PF) concentration (µg/L)day 0
C-reactive protein (CRP) concentration (mg/L)day 0
alpha-glycoprotein (AGP) concentration (g/L)day 0

Countries

Thailand

Contacts

Primary ContactNicole Stoffel, PhD
nicole.stoffel@rdm.ox.ac.uk044 632 83 93
Backup ContactPattanee Winichagoon, Prof
pattanee.win@mahidol.ac.th66-2-800-2380

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026